Regorafenib Is Associated With Increased Skeletal Muscle Loss Compared to TAS-102 in Metastatic Colorectal Cancer
Open Access
- 1 June 2019
- journal article
- research article
- Published by Elsevier in Clinical Colorectal Cancer
- Vol. 18 (2) , 159-166.e3
Abstract
No abstract availableKeywords
This publication has 33 references indexed in Scilit:
- Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trialThe Lancet, 2013
- National, regional, and global trends in body-mass index since 1980: systematic analysis of health examination surveys and epidemiological studies with 960 country-years and 9·1 million participantsThe Lancet, 2011
- Cancer cachexiaCurrent Opinion in Gastroenterology, 2010
- Sarcopenia in an Overweight or Obese Patient Is an Adverse Prognostic Factor in Pancreatic CancerClinical Cancer Research, 2009
- A practical and precise approach to quantification of body composition in cancer patients using computed tomography images acquired during routine careApplied Physiology, Nutrition, and Metabolism, 2008
- Elevated tumour interleukin-1β is associated with systemic inflammation: a marker of reduced survival in gastro-oesophageal cancerBritish Journal of Cancer, 2006
- Body composition and time course changes in regional distribution of fat and lean tissue in unselected cancer patients on palliative care—Correlations with food intake, metabolism, exercise capacity, and hormonesCancer, 2005
- Total body skeletal muscle and adipose tissue volumes: estimation from a single abdominal cross-sectional imageJournal of Applied Physiology, 2004
- Sarcopenia, Calf Circumference, and Physical Function of Elderly Women: A Cross‐Sectional StudyJournal of the American Geriatrics Society, 2003
- Cachexia in cancer patientsNature Reviews Cancer, 2002